BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer’s 36th Annual Life Science Conference, emphasizing its focus on using human aging biology to develop therapies for metabolic disease. Co-founder and CEO Kristen Fortney was joined by team members BJ Sullivan and Dov Goldstein to discuss the company’s discovery platform, lead clinical program […]